New COVID-19 vaccines to be ‘preferred’ option The vaccines, which target the XBB.1.5 Omicron variant, were approved by the TGA and will be available in Australia from next month.
ATAGI gives Moderna bivalent vaccine green light There will soon be two bivalent vaccines available to people aged 12 and over.
Updating COVID-19 vaccines ‘on the agenda’, but not sustainable Many Australians were recently recommended a fifth dose – but vaccination fatigue has researchers looking for longer term solutions.
Second bivalent booster receives ATAGI recommendation The vaccine will become available in December and is recommended for people who have not had their first or second booster doses.
TGA approves Moderna as adolescent booster An ongoing study demonstrates that the booster produces a similar immune response in this cohort to adults aged 18–25, the regulator says.
What do bivalent vaccines mean for Australia’s rollout? The first doses of Moderna’s variant-specific COVID vaccine became available this week, offering a slight advantage over previous versions.
Confusion as Government walks back bivalent dose commitment Australia will not receive 15 million doses of variant-specific vaccines from Moderna in 2022.
TGA approves second COVID-19 vaccine for youngest children The Pfizer vaccine is now approved for use in children aged six months to five years, with Moderna already available to the age group.
TGA approves vaccine booster for primary school age children Pfizer’s COVID-19 vaccine has been given the green light as a booster for children aged 5–11, with ATAGI recommendations to follow.
Government confirms bivalent vaccine supply Moderna will deliver 15 million doses of its new Omicron-specific vaccine by the end of the year, with doses set to become available next month.